---
title: "Evgen Pharma PLC (EVG.L) Publication of data in glioblastoma cells"
publisher: "Share Talk"
author: "sharetalk"
published: "2021-09-20T09:56:59+00:00"
modified: "2021-09-20T09:56:59+00:00"
date: 2021-09-20
canonical: "https://www.share-talk.com/evgen-pharma-plc-evg-l-publication-of-data-in-glioblastoma-cells/"
category: "Healthcare"
categories: ["Healthcare", "Pharmaceutical"]
tags: ["anti-inflammatory", "blood", "British Lung Foundation", "cancers", "Charity", "clinical trial", "clinical trials.", "COVID-19", "Dr Huw Jones", "Drug", "Dundee", "EVG", "Evgen", "Evgen Pharma", "Huw Jones", "LifeArc", "patients", "respiratory", "University of Dundee"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&ssl=1"
format: "news"
language: "en-GB"
---

# Evgen Pharma PLC (EVG.L) Publication of data in glioblastoma cells

**Published:** September 20, 2021
**Author:** sharetalk
**Categories:** Healthcare, Pharmaceutical
**Tags:** anti-inflammatory, blood, British Lung Foundation, cancers, Charity, clinical trial, clinical trials., COVID-19, Dr Huw Jones, Drug, Dundee, EVG, Evgen, Evgen Pharma, Huw Jones, LifeArc, patients, respiratory, University of Dundee
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&ssl=1)

---

**Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells**

**University of Auckland data**

**Evgen Pharma plc (AIM: EVG)**, a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, notes the publication of data in glioblastoma cells (GBM) generated by Dr Euphemia Leung and Prof Bruce Baguley of the University of Auckland, New Zealand in the pre-print journal BioRxIV (Leung, Wright and Baguley, 2021[https://www.biorxiv.org/content/10.1101/2021.09.14.459936v1](https://www.biorxiv.org/content/10.1101/2021.09.14.459936v1)).

The in vitro data show effectiveness of the Company’s lead asset SFX-01 in glioblastoma cells and 3D spheroids from several patients in New Zealand, together with the more commonly used commercially available cell lines. 3D spheroids are aggregations of tumour cells that more closely reflect the structure of tumours in patients. In these in vitro experiments, SFX-01 demonstrated inhibition of glioblastoma cell growth, confirming work previously announced by the Company in another academic centre.

Evgen recently announced the grant of Orphan Drug Designation in the USA for Malignant Glioma, affording the programme additional data protection and other incentives.

**Dr Huw Jones, CEO of Evgen, commented:** “This careful and well-controlled set of experiments by Dr Leung and Prof Baguley confirm work communicated to us by Dr Festuccia of the University of L’Aquila, Abruzzo, Italy and are now available through the rapid publication BioRxIV. We noted the effects observed by the Auckland group in a previous communication and the data are now available for inspection via the journal. They serve to confirm the potential efficacy of SFX-01 in cells that are arguably more disease relevant than those more commonly used.”

**Enquiries:**

**Evgen Pharma plc **

**via Walbrook**

**Dr Huw Jones, CEO**

**Richard Moulson, CFO**

**About Evgen Pharma plc**

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company’s core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company’s open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The has its headquarters at Alderley Park, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol EVG.

For further information, please visit: [www.evgen.com](http://www.evgen.com)

For research on the Company, please visit: [http://evgen.com/investors/analyst-coverage/](http://evgen.com/investors/analyst-coverage/)

---

**Original URL:** https://www.share-talk.com/evgen-pharma-plc-evg-l-publication-of-data-in-glioblastoma-cells/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*